Clinical Trial Update: TK216 in Patients With Relapsed or Refractory Ewing Sarcoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for TK216 in relapsed or refractory Ewing sarcoma (Phase 1/2) shows the study was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Sarcoma

Drugs mentioned

• TK216

Snippet

Sponsor: Oncternal Therapeutics, Inc | Conditions: Sarcoma, Ewing | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-11-07